Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme hope to “disentangle” Schering Campath deal

Executive Summary

Genzyme proposes plan to FTC that will "disentangle" Schering from a marketing agreement for Ilex' leukemia agent Campath, Genzyme Senior VP Thomas DesRosier says. FTC is reviewing Genzyme's proposed $1 bil. acquisition of Ilex and is investigating whether Campath, which is being studied by independent researchers as a transplant treatment, would overlap with Genzyme's renal transplant agent Thymoglobulin (1"The Pink Sheet" May 3, 2004, In Brief). Genzyme expects to reach an agreement in principle with FTC shortly and maintains the deal can be closed this summer...
Advertisement

Related Content

Genzyme/Ilex merger

Topics

Advertisement
UsernamePublicRestriction

Register

PS044351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel